Oct 9, 2018
CytoDyn Inc. (OTCQB: CYDY), a biotechnology company developing innovative treatments for multiple therapeutic indications, this morning detailed its strategy for completing the development of PCaTest, a novel gene-based prognostic test for prostate cancer developed by ProstaGene. Following the completion of its previously announced proposed acquisition of assets from ProstaGene, which is expected to close during the fourth quarter of 2018, CytoDyn intends to initiate a clinical study aimed at further demonstrating the superiority of the PCaTest, as compared with current genetic tests, in predicting outcomes of individuals with prostate cancer. Per the update, results are expected to be available within four months of the commencement of this clinical study. “Our plan is to complete development of the PCaTest relatively quickly and at a minimal cost to CytoDyn and to file for U.S. Food and Drug Administration (FDA) approval,” Nader Pourhassan, Ph.D., president and CEO of CytoDyn, stated in the news release. “We will gain access to the PCaTest, in addition to the technologies and patents for CCR5 antagonists in metastatic cancer from ProstaGene, with completion of this acquisition expected in the near term.”
To view the full press release, visit http://nnw.fm/yrX9S
About CytoDyn
CytoDyn is a biotechnology company developing innovative treatments for multiple therapeutic indications based on PRO 140 (leronlimab), a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 plays a key role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor is also implicated in tumor metastasis and in immune-mediated illnesses such as graft-vs-host disease (GvHD) and NASH. CytoDyn has successfully completed a Phase 3 pivotal trial with PRO 140 in combination with standard anti-retroviral therapies in HIV-infected treatment-experienced patients. The Company plans to seek FDA approval for PRO 140 in combination therapy and plans to complete the filing of a Biological License Application (BLA) in the first quarter of 2019 for that indication. CytoDyn is also conducting a Phase 3 investigative trial with PRO 140 as a once-weekly monotherapy for HIV-infected patients, and plans to initiate a registration-directed study of PRO 140 monotherapy indication, which if successful, could support a label extension. Clinical results to date from multiple trials have shown that PRO 140 can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs). Moreover, results from a Phase 2b clinical trial demonstrated that PRO 140 monotherapy can prevent viral escape in HIV-infected patients, with some patients on PRO 140 monotherapy remaining virally suppressed for more than four years. CytoDyn is also conducting a Phase 2 trial to evaluate PRO 140 for the prevention of GvHD and expects to initiate clinical trials with PRO 140 in metastatic triple-negative breast cancer in 2018. For more information, visit the company’s website at www.CytoDyn.com
More from NetworkNewsBreaks
NetworkNewsBreaks – FinCanna Capital Corp. (CSE: CALI) (OTCQB: FNNZF) Enters Restructured Agreement with Cultivation Technologies Inc. NetworkNewsBreaks – SinglePoint, Inc. (SING) CEO Discusses Impact of National TV Campaign in Interview on MoneyTV NetworkNewsBreaks – VistaGen Therapeutics, Inc. (NASDAQ: VTGN) Obtains Fast Track Designation on AV-101 to Treat Neuropathic PainAbout NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive instant SMS alerts, text STOCKS to 77948
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]
NetworkNewsWire has received compensation from CytoDyn Inc. for providing certain investor relations, marketing and social media services, including the preparation of this report, and expects to receive additional compensation for such services in the future. This compensation includes a monthly program fee.
Large enterprises may face growing constraints on innovation and artificial intelligence (AI) investments as vendor-driven software upgrades, migrations and licensing changes consume an average of 28 per cent of their software budgets, according to a report by Origina published in collaboration with Thinkers50.
Read moreDeepinder Goyal’s Temple wearable will open pre-orders on November 1, 2026, with six colour options planned for the launch edition. The device uses optical sensors to track cerebral blood flow and generates an Entropy score to indicate physiological strain.
Read moreSiemens has addressed a DLL sideloading vulnerability impacting Siemens Software Center that it said has been exploited in ClickFix attacks. The high-severity vulnerability, tracked as CVE-2026-110936 (CVSS v4 score: 8.4), could allow an attacker to place a specially-crafted DLL in a directory the application searches, resulting in execution of malicious code with the same privileges as the
Read moreClear skies permitting, skygazers could be able to spot as many as 10-20 meteors per hour as the shower peaks this week.
Read moreGetYourGuide, the global marketplace for travel experiences, and the Singapore Tourism Board (STB), have signed a two-year Memorandum of Understanding (MoU) to strengthen the development, distribution and promotion of Singapore’s diverse tourism tours and experiences to travellers around the world.
Read moreApple has announced a product launch event in Los Angeles, teasing new devices under the tagline ‘Pro and tell’. The company is expected to unveil a touchscreen OLED MacBook Pro, an M6-powered iMac and the iPad mini 8 with an OLED display.
Read moreA U.S. court on Monday granted the U.S. government's request to detain a former OpenAI engineer accused of planting a recording device in an executive conference room at the company's San Francisco office to allegedly steal sensitive secrets. In a new court filing Sunday, prosecutors revealed that Abdulrahman Alfozan, a 35-year-old Saudi national, was "in frequent communications via WhatsApp
Read moreConservationists say that, with red squirrels dwindling in the UK, Jersey is an "important refuge".
Read moreThe new chair of the Climate Change Committee is spending two days in Northern Ireland on a fact-finding mission.
Read moreThousands may be forced to evacuate as a string of events are about to collide to cause massive waves and sea level rise along the West Coast.
Read moreGLOBAL-MARKETS/VIEW-EUROPE:MORNING BID EUROPE-Korean canary in the AI coalmine
Read moreThe annual Orionid meteor shower is set to peak on the night of October 21 to 22, offering stargazers a chance to witness one of the major meteor showers of the year. Around 20 meteors can be seen per hour under ideal viewing conditions.
Read moreYOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.
